Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALL

Описание к видео Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALL

Dr Nicholas Short speaks to ecancer at EHA 2023 about a phase II study evaluating the combination of mini-hyper-CDV and inotuzumab followed by blinatumomab consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL).

He reports that over 80% of the 125 patients responded and the best outcomes were seen in patients treated in first salvage.

Dr Short also reports that the addition of blinatumomab induced improvement in relapse-free and overall survival.

Комментарии

Информация по комментариям в разработке

Похожие видео